Pure Global: USA QMSR Deadline & The Hidden Gaps Beyond ISO 13485

This episode of MedTech Global Insights dives into the critical February 2026 deadline for the FDA's new Quality Management System Regulation (QMSR). We explore why this major regulatory shift is more than just an alignment with the ISO 13485 international standard. We reveal the hidden complexities and specific FDA requirements that are catching many MedTech companies off guard. Discover why simply having an ISO 13485 certificate is not enough to ensure compliance and avoid costly delays or regulatory action in the world's largest medical device market. A European firm, fully certified under ISO 13485, had their U.S. launch abruptly halted. Their pain point was the discovery that their risk management and complaint handling processes, while compliant with ISO standards, failed to meet the specific, nuanced expectations of the FDA's new QMSR. This oversight is now costing them millions in delayed revenue and requires a frantic, last-minute overhaul of their entire quality system. 本期干货: - Why is the February 2026 QMSR deadline causing panic for even experienced MedTech companies? - What are the critical differences between ISO 13485 and the new FDA QMSR that everyone is overlooking? - How could your existing quality system lead to an FDA import alert or a complete stop-shipment order? - Are your management and leadership teams aware of their newly defined responsibilities under this regulation? - Is your internal audit program prepared to defend itself against a surprise FDA inspection under the new rules? - How can you leverage this regulatory shift to create a more efficient, globally harmonized quality system? - What specific questions should you be asking your regulatory consultants about this transition right now? Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.